Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Apr-21 1:53 PM View:  | Shaw Christine VP, Assay Development | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 101,324 | $24.05 | $2,436,840.00 | (100%) 101.32K to 0 | < 1% |
| 22-Apr-21 1:54 PM View: | Oboyle Kevin C Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 131,678 | $24.05 | $3,166,860.00 | (100%) 131.68K to 0 | < 1% |
| 22-Apr-21 1:49 PM View: | Ek John Frederick Chief Financial Officer | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 232,993 | $24.05 | $5,603,480.00 | (100%) 232.99K to 0 | < 1% |
| 22-Apr-21 1:55 PM View: | Giles Lisa M. Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 81,572 | $24.05 | $1,961,810.00 | (94%) 87.07K to 5.5K | < 1% |
| 22-Apr-21 1:49 PM View: | Mendel Scott President & CEO Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 507,198 | $24.05 | $12,198,100.00 | (81%) 622.69K to 115.49K | < 1% |
| 22-Apr-21 1:50 PM View: | Gleeson Michael SVP, Corp. Accounts | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 421,383 | $24.05 | $10,134,300.00 | (93%) 451.45K to 30.07K | < 1% |
| 22-Apr-21 1:51 PM View: | Chohan Abdul SVP Operations | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 63,750 | $24.05 | $1,533,190.00 | (100%) 63.75K to 0 | < 1% |
| 22-Apr-21 1:51 PM View: | O'Brien Scott Alexander SVP, Global Mktg & Int'l Sales | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 170,879 | $24.05 | $4,109,640.00 | (100%) 170.88K to 0 | < 1% |
| 22-Apr-21 1:55 PM View: | Giles Lisa M. Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 5,500 | $24.05 | $132,275.00 | (100%) 5.5K to 0 | < 1% |
| 22-Apr-21 1:55 PM View: | Fox James Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 182,017 | $24.05 | $4,377,510.00 | (69%) 263.1K to 81.08K | < 1% |
| 22-Apr-21 1:53 PM View: | Winkler Sarah Hollis VP, Human Resources | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 147,502 | $24.05 | $3,547,420.00 | (100%) 147.5K to 0 | < 1% |
| 22-Apr-21 1:54 PM View: | Faulkner Daryl Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 133,871 | $24.05 | $3,219,600.00 | (100%) 133.87K to 0 | < 1% |
| 22-Apr-21 1:49 PM View: | Mendel Scott President & CEO Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 115,491 | $24.05 | $2,777,560.00 | (100%) 115.49K to 0 | < 1% |
| 22-Apr-21 1:50 PM View: | Gleeson Michael SVP, Corp. Accounts | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 30,069 | $24.05 | $723,159.00 | (100%) 30.07K to 0 | < 1% |
| 22-Apr-21 1:52 PM View: | Maderazo Alan Baer VP, Qual, Reg, & Clin Affairs | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 262,180 | $24.05 | $6,305,430.00 | (100%) 262.18K to 0 | < 1% |
| 22-Apr-21 1:51 PM View: | Jensen Tyler SVP, Engineering and Tech Dev | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 212,249 | $24.05 | $5,104,590.00 | (100%) 212.25K to 0 | < 1% |
| 22-Apr-21 1:50 PM View: | Stier Eric SVP & General Counsel | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 275,974 | $24.05 | $6,637,170.00 | (100%) 275.97K to 0 | < 1% |
| 22-Apr-21 1:55 PM View: | Kagnoff Michael Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 137,319 | $24.05 | $3,302,520.00 | (100%) 137.32K to 0 | < 1% |
| 22-Apr-21 1:55 PM View: | Fox James Director | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 81,085 | $24.05 | $1,950,090.00 | (100%) 81.08K to 0 | < 1% |
| 22-Apr-21 1:50 PM View: | Harkins Michael John SVP, Sales | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 144,214 | $24.05 | $3,468,350.00 | (100%) 144.21K to 0 | < 1% |
| 22-Apr-21 1:54 PM View: | Stevenson Wade R. SVP, North America Sales | GenMark Diagnostics, Inc. (GNMK) | 22-Apr-21 | Disposition (change in control) | 50,000 | $24.05 | $1,202,500.00 | (100%) 50.0K to 0 | < 1% |
| 16-Apr-21 10:00 PM View: | Gleeson Michael SVP, Corp. Accounts | GenMark Diagnostics, Inc. (GNMK) | 14-Apr-21 | Option Exercise | 27,667 | $11.80 | $326,560.00 | 7% 422.81K to 450.48K | |
| 12-Apr-21 6:00 PM View: | Stevenson Wade R. SVP, North America Sales | GenMark Diagnostics, Inc. (GNMK) | 09-Apr-21 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
| 06-Apr-21 6:00 PM View: | Shaw Christine VP, Assay Development | GenMark Diagnostics, Inc. (GNMK) | 01-Apr-21 | Payment of Exercise | 1,730 | -- | -- | (2%) 102.2K to 100.47K | |
| 22-Mar-21 4:59 PM View: | Jensen Tyler SVP, Engineering and Tech Dev | GenMark Diagnostics, Inc. (GNMK) | 18-Mar-21 | Market Sale (Planned) | 500 | $23.88 | $11,940.00 | (< 1%) 212.39K to 211.89K | (< 1%) |
| 08-Mar-21 5:32 PM View: | Shaw Christine VP, Assay Development | GenMark Diagnostics, Inc. (GNMK) | 05-Mar-21 | Market Sale | 274 | $18.56 | $5,085.44 | (< 1%) 102.47K to 102.2K | (4%) |
| 08-Mar-21 5:33 PM View: | O'Brien Scott Alexander SVP, Global Mktg & Int'l Sales | GenMark Diagnostics, Inc. (GNMK) | 04-Mar-21 | Payment of Exercise | 735 | -- | -- | (< 1%) 171.61K to 170.88K | |
| 08-Mar-21 5:33 PM View: | Jensen Tyler SVP, Engineering and Tech Dev | GenMark Diagnostics, Inc. (GNMK) | 04-Mar-21 | Market Sale (Planned) | 500 | $18.86 | $9,430.00 | (< 1%) 212.89K to 212.39K | (3%) |
| 01-Mar-21 5:54 PM View: | Maderazo Alan Baer VP, Qual, Reg, & Clin Affairs | GenMark Diagnostics, Inc. (GNMK) | 01-Mar-21 | Market Sale (Planned) | 2,127 | $19.19 | $40,817.10 | (< 1%) 264.31K to 262.18K | |
| 01-Mar-21 5:49 PM View: | Winkler Sarah Hollis VP, Human Resources | GenMark Diagnostics, Inc. (GNMK) | 26-Feb-21 | Market Sale | 11,181 | $17.01 | $190,189.00 | (7%) 158.68K to 147.5K | (15%) |
| 01-Mar-21 5:48 PM View: | Shaw Christine VP, Assay Development | GenMark Diagnostics, Inc. (GNMK) | 26-Feb-21 | Market Sale | 3,151 | $17.03 | $53,661.50 | (3%) 105.62K to 102.47K | (15%) |
| 01-Mar-21 5:50 PM View: | Harkins Michael John SVP, Sales | GenMark Diagnostics, Inc. (GNMK) | 26-Feb-21 | Market Sale | 12,381 | $17.03 | $210,848.00 | (8%) 155.99K to 143.61K | (15%) |
| 01-Mar-21 5:51 PM View: | Gleeson Michael SVP, Corp. Accounts | GenMark Diagnostics, Inc. (GNMK) | 26-Feb-21 | Market Sale | 17,750 | $17.01 | $301,928.00 | (4%) 440.56K to 422.81K | (15%) |
| 01-Mar-21 5:51 PM View: | O'Brien Scott Alexander SVP, Global Mktg & Int'l Sales | GenMark Diagnostics, Inc. (GNMK) | 25-Feb-21 | Payment of Exercise | 9,726 | -- | -- | (5%) 181.34K to 171.61K | |
| 01-Mar-21 5:52 PM View: | Ek John Frederick Chief Financial Officer | GenMark Diagnostics, Inc. (GNMK) | 25-Feb-21 | Payment of Exercise | 19,248 | -- | -- | (8%) 252.24K to 232.99K | |
| 01-Mar-21 5:51 PM View: | Jensen Tyler SVP, Engineering and Tech Dev | GenMark Diagnostics, Inc. (GNMK) | 25-Feb-21 | Payment of Exercise | 16,734 | -- | -- | (7%) 229.62K to 212.89K | |
| 01-Mar-21 5:54 PM View: | Maderazo Alan Baer VP, Qual, Reg, & Clin Affairs | GenMark Diagnostics, Inc. (GNMK) | 25-Feb-21 | Payment of Exercise | 13,946 | -- | -- | (5%) 278.25K to 264.31K | |
| 01-Mar-21 5:53 PM View: | Mendel Scott President & CEO Director | GenMark Diagnostics, Inc. (GNMK) | 25-Feb-21 | Payment of Exercise | 41,834 | -- | -- | (6%) 664.52K to 622.69K | |
| 01-Mar-21 5:53 PM View: | Stier Eric SVP & General Counsel | GenMark Diagnostics, Inc. (GNMK) | 25-Feb-21 | Payment of Exercise | 14,642 | -- | -- | (5%) 290.62K to 275.97K | |
| 25-Feb-21 6:33 PM View: | Maderazo Alan Baer VP, Qual, Reg, & Clin Affairs | GenMark Diagnostics, Inc. (GNMK) | 25-Feb-21 | Market Sale (Planned) | 266 | $19.16 | $5,096.56 | (< 1%) 278.52K to 278.25K | |
| 25-Feb-21 6:32 PM View: | Shaw Christine VP, Assay Development | GenMark Diagnostics, Inc. (GNMK) | 24-Feb-21 | Market Sale | 259 | $19.12 | $4,952.08 | (< 1%) 105.88K to 105.62K | (< 1%) |
| 25-Feb-21 6:32 PM View: | Gleeson Michael SVP, Corp. Accounts | GenMark Diagnostics, Inc. (GNMK) | 24-Feb-21 | Market Sale | 2,463 | $19.12 | $47,092.60 | (< 1%) 443.02K to 440.56K | (< 1%) |
| 24-Feb-21 6:04 PM View: | Maderazo Alan Baer VP, Qual, Reg, & Clin Affairs | GenMark Diagnostics, Inc. (GNMK) | 24-Feb-21 | Market Sale (Planned) | 163 | $19.12 | $3,116.56 | (< 1%) 280.43K to 280.26K | |
| 25-Feb-21 6:33 PM View: | Maderazo Alan Baer VP, Qual, Reg, & Clin Affairs | GenMark Diagnostics, Inc. (GNMK) | 23-Feb-21 | Payment of Exercise | 1,744 | -- | -- | (< 1%) 280.26K to 278.52K | |
| 25-Feb-21 6:32 PM View: | Gleeson Michael SVP, Corp. Accounts | GenMark Diagnostics, Inc. (GNMK) | 23-Feb-21 | Market Sale | 1,432 | $19.35 | $27,709.20 | (< 1%) 444.46K to 443.02K | < 1% |
| 25-Feb-21 6:33 PM View: | Mendel Scott President & CEO Director | GenMark Diagnostics, Inc. (GNMK) | 23-Feb-21 | Payment of Exercise | 3,254 | -- | -- | (< 1%) 667.78K to 664.52K | |
| 25-Feb-21 6:34 PM View: | Stier Eric SVP & General Counsel | GenMark Diagnostics, Inc. (GNMK) | 23-Feb-21 | Payment of Exercise | 2,208 | -- | -- | (< 1%) 292.82K to 290.62K | |
| 25-Feb-21 6:32 PM View: | Shaw Christine VP, Assay Development | GenMark Diagnostics, Inc. (GNMK) | 23-Feb-21 | Market Sale | 166 | $19.35 | $3,212.10 | (< 1%) 106.05K to 105.88K | < 1% |
| 25-Feb-21 6:31 PM View: | O'Brien Scott Alexander SVP, Global Mktg & Int'l Sales | GenMark Diagnostics, Inc. (GNMK) | 23-Feb-21 | Payment of Exercise | 735 | -- | -- | (< 1%) 182.07K to 181.34K | |
| 25-Feb-21 6:30 PM View: | Ek John Frederick Chief Financial Officer | GenMark Diagnostics, Inc. (GNMK) | 23-Feb-21 | Payment of Exercise | 908 | -- | -- | (< 1%) 253.15K to 252.24K |
